2015
Lymphadenopathy/lymphadenitis
Shenoi S, Friedland G. Lymphadenopathy/lymphadenitis. 2015, 184-191. DOI: 10.1017/cbo9781139855952.033.Peer-Reviewed Original Research
2010
Transmission of Drug-Susceptible and Drug-Resistant Tuberculosis and the Critical Importance of Airborne Infection Control in the Era of HIV Infection and Highly Active Antiretroviral Therapy Rollouts
Shenoi SV, Escombe AR, Friedland G. Transmission of Drug-Susceptible and Drug-Resistant Tuberculosis and the Critical Importance of Airborne Infection Control in the Era of HIV Infection and Highly Active Antiretroviral Therapy Rollouts. Clinical Infectious Diseases 2010, 50: s231-s237. PMID: 20397953, PMCID: PMC3029014, DOI: 10.1086/651496.Peer-Reviewed Original ResearchConceptsInfection control strategiesResource-limited settingsHIV infectionInfection controlActive antiretroviral therapy rolloutHuman immunodeficiency virus (HIV) infectionAntiretroviral therapy rolloutTransmission of drugDrug-resistant TBImmunodeficiency virus infectionDrug-resistant tuberculosisHealth care workersAirborne infection controlNosocomial transmissionTuberculosis careVirus infectionCare workersInfectionCurrent outbreakHigh rateTBPotential benefitsMorbidityHIVTuberculosis
2009
Multidrug-resistant and extensively drug-resistant tuberculosis: consequences for the global HIV community
Shenoi S, Heysell S, Moll A, Friedland G. Multidrug-resistant and extensively drug-resistant tuberculosis: consequences for the global HIV community. Current Opinion In Infectious Diseases 2009, 22: 11-17. PMID: 19532076, PMCID: PMC3013226, DOI: 10.1097/qco.0b013e3283210020.Peer-Reviewed Original ResearchConceptsDrug-resistant tuberculosisHIV patientsHIV communityIntegration of tuberculosisIndependent risk factorCourse of treatmentCommunity-based treatmentHIV careNew rapid diagnosticsRisk factorsClinical careNegative individualsTuberculosisPatientsMultidrugRapid diagnosticsCareTreatmentSusceptibility informationMorbidityHIVInfectionMortalityPhysicians
2006
Opioid Dependence: Rationale for and Efficacy of Existing and New Treatments
Fiellin DA, Friedland GH, Gourevitch MN. Opioid Dependence: Rationale for and Efficacy of Existing and New Treatments. Clinical Infectious Diseases 2006, 43: s173-s177. PMID: 17109303, DOI: 10.1086/508180.BooksConceptsOpioid agonist treatmentOpioid dependenceAgonist treatmentHuman immunodeficiency virus (HIV) transmissionBuprenorphine/naloxone combinationNeurobiological basisOpioid withdrawalBuprenorphine treatmentHIV infectionDecreased riskNaloxone combinationOpioid receptorsGeneral physiciansMedical disordersNew treatmentsMethadoneVirus transmissionBuprenorphineTreatmentMedicationsPatientsChronicInfectionIntracellular processesPhysicians
2004
Utility of Tuberculosis Directly Observed Therapy Programs as Sites for Access to and Provision of Antiretroviral Therapy in Resource-Limited Countries
Friedland G, Karim S, Karim Q, Lalloo U, Jack C, Gandhi N, Sadr W. Utility of Tuberculosis Directly Observed Therapy Programs as Sites for Access to and Provision of Antiretroviral Therapy in Resource-Limited Countries. Clinical Infectious Diseases 2004, 38: s421-s428. PMID: 15156433, DOI: 10.1086/421407.Peer-Reviewed Original ResearchConceptsHIV infectionAntiretroviral therapyHuman immunodeficiency virus (HIV) infectionTherapy programHIV/AIDS careObserved therapy programActive antiretroviral therapyImmunodeficiency virus infectionImmune deficiency syndromeBurden of diseaseResource-limited countriesResource limited countriesHIV/AIDSHIV diseaseTuberculosis careDisease burdenDeficiency syndromeAIDS careVirus infectionTuberculosisInfectionMajor causeDiseaseTherapyInadequate access
2003
Human Immunodeficiency Virus Infection Prevention: Strategies for Clinicians
Schreibman T, Friedland G. Human Immunodeficiency Virus Infection Prevention: Strategies for Clinicians. Clinical Infectious Diseases 2003, 36: 1171-1176. PMID: 12715313, DOI: 10.1086/374359.Peer-Reviewed Original ResearchConceptsHIV infectionClinical practiceHuman immunodeficiency virus (HIV) infectionImmunodeficiency virus infectionNew HIV infectionsClinical care sitesPrevention-related activitiesClinical care settingsIntegration of preventionEffective prevention programsPublic health modelFuture prevention activitiesSpecific prevention effortsHIV diseaseVirus infectionCare settingsCare sitesBehavioral counselingClinical careMedical interventionsPrevention programsInfectionPrevention effortsHealth modelPrevention activities
1999
Tuberculosis and HIV infection
Buitrago M, Friedland G. Tuberculosis and HIV infection. Current Infectious Disease Reports 1999, 1: 105-109. PMID: 11095774, DOI: 10.1007/s11908-999-0017-3.ChaptersProphylaxis of tuberculosisExpert consensus panelAntituberculous regimensAntiretroviral medicationsHIV infectionImportant new recommendationsEquivalent efficacyDrug interactionsConsensus panelShort courseLarge-scale studiesTuberculosisProphylaxisRegimensRifampinTreatmentNew recommendationsMedicationsHIVRifabutinInfectionIndividuals
1996
Use of a quantitative cytomegalovirus (CMV) antigenemia test in evaluating HIV+ patients with and without CMV disease.
Wetherill PE, Landry ML, Alcabes P, Friedland G. Use of a quantitative cytomegalovirus (CMV) antigenemia test in evaluating HIV+ patients with and without CMV disease. JAIDS Journal Of Acquired Immune Deficiency Syndromes 1996, 12: 33-7. PMID: 8624758, DOI: 10.1097/00042560-199605010-00005.Peer-Reviewed Original ResearchMeSH KeywordsAdultAIDS-Related Opportunistic InfectionsAntibodies, MonoclonalAntigens, ViralCross-Sectional StudiesCytomegalovirusCytomegalovirus InfectionsCytomegalovirus RetinitisFemaleFluorescent Antibody TechniqueHIV SeropositivityHIV-1HumansLeukocytesMaleMiddle AgedPredictive Value of TestsRetrospective StudiesViral Matrix ProteinsViremiaConceptsCMV antigenemia testCMV diseaseAntigenemia testCMV antigenemiaHIV diseaseCytomegalovirus antigenemia testPositive CMV antigenemiaLife-threatening infectionsDiagnostic techniquesAntigenemia levelsAntigenemia resultsCMV retinitisCytomegalovirus infectionCMV cultureClinical evidenceOphthalmologic examPatientsDiseaseRapid diagnosisAntigenemiaInfectionDiagnosisQuantitative diagnostic techniqueRetinitisHIVStavudine (d4T, Zerit®)
Friedland G, Dunkle L, Cross A. Stavudine (d4T, Zerit®). Advances In Experimental Medicine And Biology 1996, 394: 271-277. PMID: 8815691, DOI: 10.1007/978-1-4757-9209-6_24.Peer-Reviewed Original ResearchConceptsAdvanced HIV-1 infectionEffects of stavudinePrior zidovudine therapyHIV-1 infectionImmunologic deteriorationAcceptable toxicityZidovudine therapyHIV diseaseClinical benefitSuch therapySurrogate markerClinical trialsDrug AdministrationStavudineTherapyBeneficial effectsU.S. FoodPatientsInfectionDiseaseAdministrationProgressionTrials
1994
Maturity of human immunodeficiency virus infection and incubation period of acquired immunodeficiency syndrome in injecting drug users
Alcabes P, Muñoz A, Vlahov D, Friedland G. Maturity of human immunodeficiency virus infection and incubation period of acquired immunodeficiency syndrome in injecting drug users. Annals Of Epidemiology 1994, 4: 17-26. PMID: 7911376, DOI: 10.1016/1047-2797(94)90038-8.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeBaltimoreCD4-Positive T-LymphocytesCohort StudiesConfidence IntervalsHIV InfectionsHIV SeroprevalenceHomosexualityHumansIncidenceLeukocyte CountLife TablesMaleModels, StatisticalNew York CityPlatelet CountRegression AnalysisSubstance Abuse, IntravenousSurvival RateTime FactorsConceptsHIV infectionDrug usersImmunodeficiency syndromeMedian timeCombined cohortHomosexual menHuman immunodeficiency virus (HIV) infectionHuman immunodeficiency virus (HIV) epidemicPercent of CD4Immunodeficiency virus infectionIncident HIV infectionProduct-limit methodMarkers of maturityHIV incubation distributionsPlatelet countVirus infectionLarge cohortSeroconversionCohortInfectionConfidence intervalsIncubation distributionAIDSVirus epidemicPopulation groups
1991
Human T Lymphotropic Virus Type II (HTLV-II) Infection in a Cohort of New York Intravenous Drug Users: An Old Infection?
Khabbaz R, Hartel D, Lairmore M, Horsburgh C, Schoenbaum E, Roberts B, Hartley T, Friedland G. Human T Lymphotropic Virus Type II (HTLV-II) Infection in a Cohort of New York Intravenous Drug Users: An Old Infection? The Journal Of Infectious Diseases 1991, 163: 252-256. PMID: 1988509, DOI: 10.1093/infdis/163.2.252.Peer-Reviewed Original ResearchConceptsIntravenous drug usersHuman T-lymphotropic virus type II (HTLV-II) infectionHTLV-II infectionType II infectionPolymerase chain reactionRisk factorsHTLV-IIDrug usersHuman immunodeficiency virus (HIV) infectionHIV infection statusImmunodeficiency virus infectionIntravenous drug useMethadone maintenance programTransfusion historyNeedle sharingVirus infectionSerologic resultsSex partnersDrug useShooting galleriesEndemic infectionInfectionOlder ageInfection statusOld infectionDemographic characteristics, drug use, and sexual behavior of i.v. drug user with AIDS in Bronx, New York.
Schrager L, Friedland G, Feiner C, Kahl P. Demographic characteristics, drug use, and sexual behavior of i.v. drug user with AIDS in Bronx, New York. Public Health Reports 1991, 106: 78-84. PMID: 1899944, PMCID: PMC1580205.Peer-Reviewed Original ResearchConceptsDrug usersDemographic characteristicsDrug useHuman immunodeficiency virus (HIV) infectionImmunodeficiency virus infectionIntravenous drug usersMontefiore Medical CenterMethadone maintenance programSharing of needlesInjection of drugsSexual behaviorDrug use behaviorsDrug use practicesHIV infectionImmunodeficiency syndromeVirus infectionMedical CenterEpidemiologic informationShooting galleriesCocaine useAIDSInjection episodesSexual practicesEarly ageInfection
1990
Additional evidence for lack of transmission of HIV infection by close interpersonal (casual) contact
Friedland G, Kahl P, Saltzman B, Rogers M, Feiner C, Mayers M, Schable C, Klein R. Additional evidence for lack of transmission of HIV infection by close interpersonal (casual) contact. AIDS 1990, 4: 639-644. PMID: 2118767, DOI: 10.1097/00002030-199007000-00005.Peer-Reviewed Original ResearchConceptsHousehold contactsHIV infectionAIDS patientsClose interpersonal contactNon-sexual contactsPossibility of transmissionAdult patientsHIV antibodiesMedian durationMedian timeP24 antigenHIV transmissionPhysical examinationSerum antibodiesPatientsLast contactLack of transmissionLast evaluationInitial evaluationMonthsInfectionHIVSymptomsAntigenAIDS
1989
Risk Factors for Human Immunodeficiency Virus Infection in Intravenous Drug Users
Schoenbaum E, Hartel D, Selwyn P, Klein R, Davenny K, Rogers M, Feiner C, Friedland G. Risk Factors for Human Immunodeficiency Virus Infection in Intravenous Drug Users. New England Journal Of Medicine 1989, 321: 874-879. PMID: 2770823, DOI: 10.1056/nejm198909283211306.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virus (HIV) infectionImmunodeficiency virus infectionIntravenous drug usersPercentage of injectionsRisk factorsHIV antibodiesDrug usersIntravenous drugsVirus infectionSex partnersSeroprevalence of HIVIndependent risk factorOnly risk factorMethadone treatment programsNumber of injectionsNon-Hispanic whitesHeterosexual sex partnersHIV infectionLast injectionUsed needlesHigh seroprevalenceDrug useShooting galleriesHIVInfectionCervical and vaginal squamous cell abnormalities in women infected with human immunodeficiency virus.
Schrager L, Friedland G, Maude D, Schreiber K, Adachi A, Pizzuti D, Koss L, Klein R. Cervical and vaginal squamous cell abnormalities in women infected with human immunodeficiency virus. JAIDS Journal Of Acquired Immune Deficiency Syndromes 1989, 2: 570-5. PMID: 2555473.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusHuman papillomavirus infectionPapillomavirus infectionImmunodeficiency virusLower genital tract neoplasiaGenital HPV infectionGenital tract neoplasiaSquamous cell abnormalitiesHPV infectionSquamous abnormalitiesHIV infectionHigh prevalenceCytological abnormalitiesNeoplastic disordersCervicovaginal smearsHigh riskCell abnormalitiesBlinded fashionInfectionWomenAbnormalitiesCellular changesFurther studiesVirusRisk
1988
Increased risk of bacterial pneumonia in HIV-infected intravenous drug users without AIDS
Selwyn P, Feingold A, Hartel D, Schoenbaum E, Alderman M, Klein R, Friedland G. Increased risk of bacterial pneumonia in HIV-infected intravenous drug users without AIDS. AIDS 1988, 2: 267-272. PMID: 3140832, DOI: 10.1097/00002030-198808000-00005.Peer-Reviewed Original ResearchConceptsIntravenous drug usersIntravenous drug useBacterial pneumoniaHIV infectionDrug usersDrug useActive intravenous drug useCommunity-acquired bacterial pneumoniaCumulative yearly incidenceMethadone maintenance programSeronegative subjectsSeropositive patientsSeropositive subjectsStudy entryOpportunistic infectionsYearly incidencePneumoniaHemophilus influenzaeStreptococcus pneumoniaeSeropositivesHIVAIDSInfectionStudy periodIncidenceAIDS and Compassion
Friedland G. AIDS and Compassion. JAMA 1988, 259: 2898-2899. PMID: 3367458, DOI: 10.1001/jama.1988.03720190066034.Peer-Reviewed Original ResearchTransmission of the human immunodeficiency virus: an updated review.
Friedland G, Klein R. Transmission of the human immunodeficiency virus: an updated review. International Nursing Review 1988, 35: 44-52, 54. PMID: 3283068.Peer-Reviewed Original Research
1986
Mycobacterium tuberculosis Bacteremia in the Acquired Immunodeficiency Syndrome
Saltzman B, Motyl M, Friedland G, McKitrick J, Klein R. Mycobacterium tuberculosis Bacteremia in the Acquired Immunodeficiency Syndrome. JAMA 1986, 256: 390-391. PMID: 3088290, DOI: 10.1001/jama.1986.03380030092036.Peer-Reviewed Original ResearchConceptsAcquired Immunodeficiency SyndromeImmunodeficiency syndromeCellular immunityM tuberculosisMycobacterium avium-intracellulare infectionDisease Control case definitionMycobacterium tuberculosis bacteremiaIntravenous drug abusersUnusual malignant neoplasmFive-year historyIntravenous heroinOpportunistic infectionsDisseminated infectionMalignant neoplasmsCase definitionBacteremiaCocaine abuseDrug abusersBacterial infectionsInfectionMycobacterium tuberculosisWeight lossTuberculosisPatientsSyndromeLack of Transmission of HTLV-III/LAV Infection to Household Contacts of Patients with AIDS or AIDS-Related Complex with Oral Candidiasis
Friedland G, Saltzman B, Rogers M, Kahl P, Lesser M, Mayers M, Klein R. Lack of Transmission of HTLV-III/LAV Infection to Household Contacts of Patients with AIDS or AIDS-Related Complex with Oral Candidiasis. New England Journal Of Medicine 1986, 314: 344-349. PMID: 3456076, DOI: 10.1056/nejm198602063140604.Peer-Reviewed Original ResearchConceptsHTLV-III/LAVHousehold contactsOral candidiasisHuman T-cell lymphotropic virus type III/lymphadenopathy-associated virusHTLV-III/LAV infectionType III/lymphadenopathy-associated virusNonsexual household contactsLymphadenopathy-associated virusEvidence of infectionRisk of infectionRisk of transmissionNonsexual contactImmunodeficiency syndromeAIDS patientsPhysical examinationSerum antibodiesIndex patientsPatientsLack of transmissionSexual partnersAIDSInfectionFive-year-old childrenCandidiasisSame household